CO5251452A1 - Oxazoles sustituidos y derivados de tiazoles como activadores de alfa hppar - Google Patents

Oxazoles sustituidos y derivados de tiazoles como activadores de alfa hppar

Info

Publication number
CO5251452A1
CO5251452A1 CO00091770A CO00091770A CO5251452A1 CO 5251452 A1 CO5251452 A1 CO 5251452A1 CO 00091770 A CO00091770 A CO 00091770A CO 00091770 A CO00091770 A CO 00091770A CO 5251452 A1 CO5251452 A1 CO 5251452A1
Authority
CO
Colombia
Prior art keywords
tiazols
oxazols
hppar
alfa
activators
Prior art date
Application number
CO00091770A
Other languages
English (en)
Inventor
Michael Lawrence Sierra
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9928561.1A external-priority patent/GB9928561D0/en
Priority claimed from GB0003500A external-priority patent/GB0003500D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5251452A1 publication Critical patent/CO5251452A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto de formula (I) y sales farmacéuticamente aceptables, solvatos y ésteres hidrolisables del mismo.<EMI FILE="00091770_1" ID="1" IMF=JPEG >caracterizado porqueX1 representa O ó S;R1 y R2, independientemente representan H, halógeno, -CH3 y -OCH3;n representa 1 ó 2 ;X2 representa NH, NCH3 u O;uno de Y y Z es N, y el otro es O ó S;R3 representa fenilo o piridilo (en donde el n está en la posición 2 ó 3) y está opcionalmente sustituido por uno o más de halógeno, NO2, NH2, CF3, OCF3, alquilo OC1-6 recto o ramificado, alquilo C1-6 recto o ramificado, alquilo, alquenilo o alquinilo con la condición de que cuando R3 es piridilo, el N está no sustituido;R4 representa CF3 o CH3.
CO00091770A 1999-12-02 2000-11-30 Oxazoles sustituidos y derivados de tiazoles como activadores de alfa hppar CO5251452A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928561.1A GB9928561D0 (en) 1999-12-02 1999-12-02 Chemical compounds
GB0003500A GB0003500D0 (en) 2000-02-15 2000-02-15 Chemical compounds

Publications (1)

Publication Number Publication Date
CO5251452A1 true CO5251452A1 (es) 2003-02-28

Family

ID=26243654

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00091770A CO5251452A1 (es) 1999-12-02 2000-11-30 Oxazoles sustituidos y derivados de tiazoles como activadores de alfa hppar

Country Status (27)

Country Link
US (1) US6518290B1 (es)
EP (1) EP1244642B1 (es)
JP (1) JP3884290B2 (es)
KR (1) KR100706735B1 (es)
CN (1) CN1184215C (es)
AR (1) AR035631A1 (es)
AT (1) ATE265442T1 (es)
AU (1) AU758758B2 (es)
BR (1) BR0016067A (es)
CA (1) CA2393190A1 (es)
CO (1) CO5251452A1 (es)
CZ (1) CZ20021903A3 (es)
DE (1) DE60010333T2 (es)
DK (1) DK1244642T3 (es)
ES (1) ES2219423T3 (es)
GC (1) GC0000215A (es)
HK (1) HK1047435B (es)
HU (1) HUP0203532A3 (es)
IL (2) IL149582A0 (es)
MX (1) MXPA02005456A (es)
NO (1) NO323135B1 (es)
PE (1) PE20011010A1 (es)
PL (1) PL356772A1 (es)
PT (1) PT1244642E (es)
TR (2) TR200401772T4 (es)
TW (1) TW555753B (es)
WO (1) WO2001040207A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317885B1 (it) * 2000-08-01 2003-07-15 Sigma Tau Ind Farmaceuti Uso di fibrati per la preparazione di un medicamento utile neltrattamento dell'insufficienza cardiaca congestizia.
US6787552B2 (en) * 2000-08-11 2004-09-07 Nippon Chemiphar Co., Ltd. PPAR delta activators
UA82048C2 (uk) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
JP2004517100A (ja) * 2000-12-20 2004-06-10 グラクソ　グループ　リミテッド ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031109D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0113232D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical process
GB0113233D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
PT1424330E (pt) * 2001-08-10 2011-12-22 Nippon Chemiphar Co Activador do receptor ä responsivo a proliferadores peroxissomais
GT200200188A (es) * 2001-09-24 2003-06-25 Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad
DE60208815T2 (de) * 2001-10-12 2006-07-20 Bayer Pharmaceuticals Corp., West Haven Phenyl substituierte 5-gliedrige stickstoff enthaltende heterocyclen zur behandlung von fettleibigkeit
JP4383177B2 (ja) 2002-03-01 2009-12-16 スミスクライン ビーチャム コーポレーション ｈＰＰＡＲ活性化剤
KR100474202B1 (ko) * 2002-05-04 2005-03-08 강헌중 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체
AU2003241579B9 (en) 2002-06-19 2009-07-30 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
GB0214139D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
US7273866B2 (en) 2002-12-20 2007-09-25 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as KCNQ modulators
US6933308B2 (en) 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
DE602004010889T2 (de) * 2003-02-14 2008-12-11 Eli Lilly And Co., Indianapolis Sulfonamid-derivate als ppar-modulatoren
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
DE10331496A1 (de) * 2003-07-01 2005-01-27 Bayer Cropscience Ag Verfahren zum Herstellen von Difluoracetessigsäurealkylestern
US7541475B2 (en) 2003-07-30 2009-06-02 Abbott Laboratories Substituted thiazoles
US20050027128A1 (en) * 2003-07-30 2005-02-03 Robbins Timothy A. Substituted thiazoles
TW200526588A (en) * 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
WO2005095364A1 (ja) * 2004-03-30 2005-10-13 Daiichi Pharmaceutical Co. Ltd. フェノキシ酢酸誘導体及びそれを用いた医薬
JP2007230868A (ja) * 2004-03-30 2007-09-13 Dai Ichi Seiyaku Co Ltd 二環性化合物及びそれを用いた医薬
DE102004016845A1 (de) * 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
US20070202179A1 (en) * 2004-04-09 2007-08-30 FAULKNER Patrick Low Dose Pharmaceutical Products
JP2007284352A (ja) * 2004-08-05 2007-11-01 Dai Ichi Seiyaku Co Ltd ピラゾール誘導体
KR20070050475A (ko) * 2004-08-11 2007-05-15 교린 세이야꾸 가부시키 가이샤 신규 환상 아미노 안식향산 유도체
JP2008530154A (ja) * 2005-02-15 2008-08-07 エフ．ホフマン−ラ ロシュ アーゲー Ｐｐａｒアクチベーターとしてのアミド誘導体
EP1862464A4 (en) * 2005-03-23 2010-08-25 Kyorin Seiyaku Kk NEW CYCLIC AMINOPHENYL ALKANIC ACID DERIVATIVE
JP3795515B1 (ja) 2005-08-10 2006-07-12 善典 中川 半導体光電気化学セルの製造方法
RU2435764C2 (ru) 2006-04-18 2011-12-10 Ниппон Кемифар Ко., Лтд. АГЕНТ, АКТИВИРУЮЩИЙ РЕЦЕПТОР, АКТИВИРУЕМЫЙ ПРОЛИФЕРАТОРАМИ ПЕРОКСИСОМ δ
WO2008035359A2 (en) * 2006-06-12 2008-03-27 Cadila Healthcare Limited Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
RU2480453C2 (ru) 2007-03-08 2013-04-27 Альбирео Аб Новые соединения
UA105758C2 (uk) * 2007-07-19 2014-06-25 Х. Луннбек А/С 5-членні гетероциклічні аміди та споріднені сполуки
KR100882261B1 (ko) 2007-07-25 2009-02-06 삼성전기주식회사 인쇄회로기판의 제조 방법 및 장치
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
NZ588612A (en) 2008-04-15 2012-08-31 Nippon Chemiphar Co Benzothiophen derivatives as activators of peroxisome proliferator activated receptor (PPAR)
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010071813A1 (en) * 2008-12-19 2010-06-24 Aryx Therapeutics, Inc. AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
HUP0003881A3 (en) * 1997-10-02 2001-04-28 Sankyo Co Amidocarboxylic acid derivatives
KR100620337B1 (ko) * 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제

Also Published As

Publication number Publication date
ATE265442T1 (de) 2004-05-15
AU758758B2 (en) 2003-03-27
NO20022467D0 (no) 2002-05-24
EP1244642A1 (en) 2002-10-02
PE20011010A1 (es) 2001-10-18
TW555753B (en) 2003-10-01
KR20020058073A (ko) 2002-07-12
AU2003001A (en) 2001-06-12
BR0016067A (pt) 2002-08-06
DE60010333T2 (de) 2005-06-16
HUP0203532A2 (hu) 2003-02-28
AR035631A1 (es) 2004-06-23
CZ20021903A3 (cs) 2003-01-15
TR200401772T4 (tr) 2004-09-21
CN1184215C (zh) 2005-01-12
US6518290B1 (en) 2003-02-11
HK1047435A1 (en) 2003-02-21
DK1244642T3 (da) 2004-08-16
GC0000215A (en) 2006-03-29
PL356772A1 (en) 2004-07-12
PT1244642E (pt) 2004-09-30
IL149582A0 (en) 2002-11-10
NO20022467L (no) 2002-07-26
EP1244642B1 (en) 2004-04-28
KR100706735B1 (ko) 2007-04-13
NO323135B1 (no) 2007-01-08
HUP0203532A3 (en) 2005-01-28
MXPA02005456A (es) 2002-11-29
DE60010333D1 (de) 2004-06-03
CN1402716A (zh) 2003-03-12
IL149582A (en) 2008-11-26
ES2219423T3 (es) 2004-12-01
WO2001040207A1 (en) 2001-06-07
JP2003515597A (ja) 2003-05-07
JP3884290B2 (ja) 2007-02-21
TR200201473T2 (tr) 2002-09-23
CA2393190A1 (en) 2001-06-07
HK1047435B (zh) 2004-11-26

Similar Documents

Publication Publication Date Title
CO5251452A1 (es) Oxazoles sustituidos y derivados de tiazoles como activadores de alfa hppar
CO5271690A1 (es) Derivados de pirimidina
BG106473A (en) Uracil substituted phenyl sulfamoyl carboxamides
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
BR0314980A (pt) Inibidores de hidrolase de amida de ácido graxo
EA200600509A1 (ru) Соединения пиримидотиофена
ATE542805T1 (de) Ppar-delta aktivatoren
CO5611131A2 (es) Derivados de 5-feniltiazol y su uso como inhibidores de pi3 cinasa
MXPA02011466A (es) Derivados de fenilglicina..
CO5160347A1 (es) Derivados de acido carbamico
NO20035316D0 (no) Tiazol- eller oksazol-derivater som er anvendelige ved behandling av kardiovaskul¶re og beslektede sykdommer
DE69927039D1 (de) Synthetische analoge des ecteinascidin-743
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
CO5200757A1 (es) Derivados de 4-indol benzamidas con actividad contra la osteoporosis, sus sales farmaceuticamente aceptables y composiciones farmaceuticas que los contienen
TR200200076T2 (tr) Oral yoldan aktif androjenler
CO5700781A2 (es) Agonistas morfolinicos de la dopamina
UY25211A1 (es) Inhibidores de isoquinolinilguanidina uroquinasa
DE69821530D1 (de) Dihydrobenzifurane
ES369802A1 (es) Un procedimiento para preparar derivados de n-fenilsuccini-mida.
CO5540297A2 (es) Derivados de oxazol/tiazol activadores del receptor hppar- alfa
TW200606163A (en) Imidazopyridine compound
CO5540311A2 (es) Derivados de pirimidina utiles como inhibidores de cox-2 selectivos
EA200600608A1 (ru) Производные имидазопиридина как ингибиторы индуцируемой no-синтазы
CO5180536A1 (es) Inhibidores de proteasas catepsina

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed